Key Financial Figures (Standalone)
- Revenue from Operations: Increased to ₹21,259.48 lakh (₹212.59 crore) from ₹20,327.85 lakh (₹203.28 crore) in previous year
- Total Income: ₹21,355.73 lakh (₹213.56 crore) vs ₹20,546.72 lakh (₹205.47 crore) YoY
- Profit Before Tax: ₹2,800.61 lakh (₹28.01 crore) vs ₹3,271.13 lakh (₹32.71 crore) YoY
- Profit After Tax: ₹2,077.20 lakh (₹20.77 crore) vs ₹2,475.49 lakh (₹24.75 crore) YoY
- EPS: ₹18.24 (basic and diluted) vs ₹26.06 YoY
Key Financial Figures (Consolidated)
- Revenue from Operations: ₹21,482.91 lakh (₹214.83 crore)
- Total Income: ₹21,549.41 lakh (₹215.49 crore)
- Profit Before Tax: ₹2,688.87 lakh (₹26.89 crore)
- Profit After Tax: ₹1,965.46 lakh (₹19.65 crore)
- Attributable to Parent: ₹1,965.82 lakh (₹19.66 crore)
Share Capital Structure
- Authorized Capital: 2,50,00,000 equity shares of ₹10 each (₹25.00 crore)
- Issued, Subscribed & Paid-up: 1,20,99,000 equity shares of ₹10 each (₹12.10 crore)
- Previous Year: 94,99,000 equity shares (₹9.50 crore)
- Change: Increase due to IPO issuance of 26,00,000 fresh equity shares
IPO Details and Utilization
- IPO Date: July 2025 (opened 7th July, closed 9th July 2025)
- Listing Date: 14th July 2025 on BSE SME Platform
- Issue Size: ₹8,008.42 lakh (₹80.08 crore)
- Issue Price: ₹248 per share (face value ₹10, premium ₹238)
- Fresh Issue: 26,00,000 shares
- Offer for Sale: 6,29,200 shares by promoter selling shareholders
- Funds Utilization:
- Manufacturing facility through subsidiary: ₹457.00 lakh (against planned ₹3,468.33 lakh)
- Debt repayment: ₹2,000.00 lakh (fully utilized)
- General corporate purpose: ₹954.00 lakh (against planned ₹980.00 lakh)
Subsidiaries
- Easy Raw Materials Private Limited: Wholly-owned subsidiary, CIN U51909MH2020PTC351813
- Vinstar Biotech Private Limited: Wholly-owned subsidiary, CIN U21001MH2023PTC399095
- Subsidiary Financials: Both subsidiaries reported losses for FY 2025-26
Corporate Actions and Appointments
- 7th AGM: Scheduled for 19th September 2026 through video conferencing
- Director Reappointment: Mr. Shailesh Vinodrai Mehta (DIN: 10563871) retiring by rotation, recommended for reappointment
- Statutory Auditors: Recommendation to appoint M/s Prem Chand Jain & Co. (FRN: 000066C) for 5 years from conclusion of 7th AGM to 12th AGM at remuneration of ₹3.90 lakh per annum plus GST
- Secretarial Auditor: Recommendation to appoint M/s Nirmal Tiwari & Associates for 5 years at remuneration of ₹75,000 for FY 2026-27
- Internal Auditor: M/s N.R. Tibrewala & Co LLP for FY 2025-26; M/s Vinay Bhushan & Associates appointed for FY 2026-27
Board and Committee Composition
- Board Members: 6 directors (1 Managing Director, 2 Executive Directors, 3 Independent Directors)
- Audit Committee: Mr. Rajesh Vashu Kalro (Chairman), Mr. Anirudh Brijkishore Ruia, Mr. Ankit Shailesh Mehta
- Stakeholders Relationship Committee: Mr. Anirudh Brijkishore Ruia (Chairman), Mr. Abhishek Sunil Kamdar, Ms. Parul Shailesh Mehta
- Nomination and Remuneration Committee: Mr. Abhishek Sunil Kamdar (Chairman), Mr. Anirudh Brijkishore Ruia, Mr. Rajesh Vashu Kalro
- CSR Committee: Mr. Rajesh Vashu Kalro (Chairman), Mr. Abhishek Sunil Kamdar, Mr. Ankit Shailesh Mehta
Dividend and Reserves
- Dividend: No dividend recommended for FY 2025-26 to conserve financial resources
- Reserves and Surplus: ₹11,895.90 lakh (₹118.96 crore) as on 31st March 2026
CSR Activities
- CSR Obligation: ₹43.53 lakh (2% of average net profit of ₹217.63 lakh)
- CSR Expenditure: ₹44.41 lakh (exceeding obligation by ₹0.88 lakh)
- Focus Areas: Healthcare (preventive healthcare) and livelihood enhancement projects
- Implementing Agencies: Hetal Apurva Foundation and Inner Medical Foundation and Research Institute
Key Operational Highlights
- Business: Trading and value-added processing of nutraceutical, health and sports-supplement ingredients
- Product Categories: Amino Acids, Health Supplements, Herbal Extracts, Nucleotides, Proteins, Sports Nutrition, and Vitamins
- Manufacturing Facility: Bhiwandi, Thane with capacity of 540 MT per annum grinding and 450 MT per annum blending
- Employee Strength: 30 employees (16 Male, 14 Female)
Regulatory and Compliance Matters
- SEBI Compliance: All regulations complied with including appointment of auditors, filing of financial results, and corporate governance requirements
- Secretarial Audit: No qualifications or adverse remarks in secretarial audit report
- Statutory Audit: No qualifications in audit report, though emphasis drawn to customs duty matter
- Customs Duty Matter: ₹1,474.26 lakh paid shown as recoverable from government authorities based on management assessment
Related Party Transactions
All transactions with related parties were conducted at arm's length and in ordinary course of business. Significant transactions include:
- Interest income from subsidiaries: ₹27.55 lakh from Easy Raw Materials and ₹2.52 lakh from Vinstar Biotech
- Rent income from subsidiaries: ₹1.20 lakh each from both subsidiaries
- Sales to Vinstar Biotech: ₹172.78 lakh
Risk Factors
Identified risks include dependence on raw material supply, geographical concentration in Mumbai region, exposure to commodity price volatility, regulatory changes in nutraceutical sector, working capital intensity, and integration risk with subsidiaries.
Outlook
The company aims to focus on scaling up processing operations, integrating subsidiaries, deepening customer base, and strengthening working capital management. The nutraceutical industry in India continues to offer growth opportunities driven by health awareness and preventive healthcare trends.
AGM Business
Ordinary Business:
1. Adoption of audited financial statements for FY 2025-26
2. Reappointment of Mr. Shailesh Vinodrai Mehta as director
3. Appointment of statutory auditors
Special Business:
4. Appointment of secretarial auditors
Voting Arrangements
- Remote e-Voting: From 16th September 2026 (9:00 AM) to 18th September 2026 (5:00 PM)
- Cut-off Date: 12th September 2026
- Scrutinizer: M/s Nirmal Tiwari & Associates
- AGM Mode: Video conferencing/OAVM only, no physical attendance